AzTrials
AzTrials

Implantable Cardioverter Defibrillator (ICD)BELIEVENCT07156851

Observational BELgian Registry of Implanted EV-ICD to Evaluate Parameters and Complications of the New Device in Real World Settings

An observational study of Implantable Cardioverter Defibrillator (ICD), run by AZ Sint-Jan AV at 7 sites in Belgium.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The goal of this observational study is to follow all patients implanted with extravascular implantable cardioverter-defibrillators (EV-ICDs) in Belgium throughout the lifetime of the devices. Read more about this study

Who is it for?
Ages 18 years and older
How many people
100 participants
Where
7 sitesBelgium
Study dates
25 Sep 2025to 1 Jul 2040
How long will I take part?
15 Years
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients who underwent or will undergo an EV-ICD implantation in Belgium, whether successful or not, can be included in this registry.

Who may be able to join

  • At least 18 years old
  • Previous or planned EV-ICD implantation (successful or not)
  • Informed consent signed

Who cannot join

  • Patients who did not undergo any step of the implantation procedure

Trial locations and contacts

7 sites in 1 country. Contact the study team or a site near you to ask about taking part.

7 sites in 1 country

Belgium7 sites, 7 recruiting
  • UZA

    Antwerp

    Dr. Wim Huybrechts

    Recruiting
  • ZAS Middelheim

    Antwerp

    Dr. Michael Wolf

    Recruiting
  • AZ Sint-Jan Brugge

    Bruges

    Dr. Nicolas Blankoff, +3250452670, cardiologie@azsintjan.be

    Recruiting
  • UCL Saint-Luc

    Brussels

    Dr. Sébastien Marchandise

    Recruiting
  • UZ Brussel

    Brussels

    Dr. Ingrid Overeinder

    Recruiting
  • UZ Gent

    Ghent

    Dr. Liesbeth Timmers

    Recruiting
  • CHU Liège

    Liège

    Dr. Caroline Piette

    Not yet recruiting

Other trials in Belgium

About this study

The goal of this observational study is to follow all patients implanted with extravascular implantable cardioverter-defibrillators (EV-ICDs) in Belgium throughout the lifetime of the devices. The main goal of the study is to keep track of:

  • all parameters of the device
  • complications
  • arrhythmia detection and therapy delivery
  • clinical endpoints (quality of life, cardiac and infectious events) Participants who underwent or will undergo an EV-ICD implantation as part of their regular medical care will be asked if data can be collected from their medical record. No additional tasks are required for the study.
Read the detailed description

The BELIEVE registry (BELgian registry of Implanted EV-ICDs to Evaluate parameters and complications) is a multicenter, observational registry designed to gather real-world data on the use of extravascular implantable cardioverter-defibrillators (EV-ICDs) in Belgium. This new generation of ICD technology offers the potential advantages of both subcutaneous (S-ICD) and transvenous (TV-ICD) devices, with the lead placed under the sternum. This position enables pacing capabilities and more accurate arrhythmia detection while aiming to minimize lead-related complications seen in previous ICD systems.

Given the relatively recent introduction of EV-ICDs, it is essential to monitor their performance and clinical outcomes in routine clinical settings. While initial trials have demonstrated feasibility and safety, real-world data are crucial for understanding long-term efficacy, complication rates, therapy effectiveness, device longevity, and overall patient outcomes. The BELIEVE registry was therefore established to support this need, offering a structured framework to follow patients over time and improve clinical practice related to EV-ICDs.

The registry is both retrospective and prospective, non-randomized, and will include all patients in Belgium who undergo (or have undergone) an EV-ICD implantation-regardless of whether the procedure was successful. Participating centers will aim to enroll an initial cohort of 100 patients over a 4-year period, although the number of patients and study duration may be extended. The total planned study period is 15 years, with patients followed throughout the life of their device.

Inclusion criteria are broad: participants must be at least 18 years old, have had or be scheduled for an EV-ICD implantation (even if unsuccessful), and must provide informed consent. Patients who did not undergo any part of the implantation procedure are excluded.

Data will be collected at baseline, during the procedure, and during scheduled follow-up visits (at 1-3 months, 6 months, and then at least annually). Information will include demographic and clinical characteristics, medical history, device data, arrhythmia detection, therapy delivery, programming changes, complications, and patient-reported outcomes.

Keywords
Extravascular implantable cardioverter-defibrillator, EV-ICD

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of delivered therapies (ATP and shocks)

    Total number of therapies delivered by the device, including antitachycardia pacing and shocks (Unit: count)

    Measured: Lifetime of the device (up to 15 years)

  2. Proportion of delivered therapies that were appropriate

    Percentage of therapies delivered by the device that were adjudicated as appropriate (i.e., delivered for true ventricular arrhythmia).

    Measured: Lifetime of the device (up to 15 years)

  3. Proportion of delivered therapies that were successful

    Percentage of therapies delivered by the device that successfully terminated the targeted ventricular arrhythmia.

    Measured: Lifetime of the device (up to 15 years)

  4. Tracking procedural and device-related complications

    Tracking procedural and device-related complications during the lifetime of the device

    Measured: Lifetime of the device (up to 15 years)

Secondary outcomes (9)
  1. Change in sensing amplitude over time

    Change in device-recorded sensing amplitude (in mV) from implantation to follow-up visits.

    Measured: Lifetime of the device (up to 15 years)

  2. Change in pacing threshold over time

    Change in pacing threshold (in Volt) measured during device follow-up from implantation to 15 years.

    Measured: Lifetime of the device (up to 15 years)

  3. Change in lead impedance over time

    Change in lead impedance (in Ohm) from implantation to 15 years of follow-up.

    Measured: Lifetime of the device (up to 15 years)

  4. Change in battery longevity estimates over time

    Change in estimated battery longevity (in years) as reported by the device at each follow-up visit.

    Measured: Lifetime of the device (up to 15 years)

  5. Accuracy of arrhythmia detection by the device

    Proportion of arrhythmia episodes correctly classified by the device (%)

    Measured: Lifetime of the device (up to 15 years)

  6. Summary of device reprogramming

    Summary of every device reprogramming including reason for changes

    Measured: Lifetime of the device (up to 15 years)

  7. Number of participants with major adverse cardiac events (MACE)

    Number of participants experiencing major adverse cardiac events, including cardiovascular death, hospitalization for heart failure, myocardial infarction, or stroke.

    Measured: Lifetime of the device (up to 15 years)

  8. Number of participants with device-related infections

    Number of participants with infections requiring antibiotic treatment or device/system extraction.

    Measured: Lifetime of the device (up to 15 years)

  9. Number of participants reporting device-related complaints

    Number of participants reporting device-related symptoms or complaints (e.g., inappropriate shocks, pain at device site).

    Measured: Lifetime of the device (up to 15 years)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Sep 2025
  2. Study start25 Sep 2025
  3. Primary completion1 Jul 2040 (estimated)
  4. Study completion1 Jul 2040 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
Target duration
15 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07156851
Sponsor's protocol ID
BELIEVE
Acronym
BELIEVE
Status last verified
Sep 2026
First submitted
18 Mar 2025
Last updated
15 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in